A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00171704

Enrollment

263

Registered

2005-09-15

Start date

2005-04-30

Completion date

2011-03-31

Last updated

2017-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women

Keywords

Breast Cancer, Letrozole, Bone Mineral Density, Bone Markers, Serum lipid, Postmenopausal

Brief summary

Estrogen is known to be a regulator of bone and lipid metabolism. Letrozole is a potent inhibitor of estrogen synthesis. This study evaluated the effects of letrozole and tamoxifen on bone and lipid metabolism in postmenopausal women with resected, receptor positive early breast cancer.

Interventions

DRUGLetrozole

2.5 mg tablets and supplied in bottles with 6-monthly supplies.

DRUGTamoxifen

20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Female * Post-menopausal hormone status defined as: * Patients with menostasis (amenorrhea) \> 12 months or history of oophorectomy. * Patients ≥ 55 years with history of hysterectomy or having continued/renewed menstruation on cyclic hormone treatment. * Patients of 50-54 years: Menopausal status was determined on the basis of follicle-stimulating hormone (FSH)/luteinizing hormone (LH) values. * Histologically confirmed resected breast cancer and eligible for adjuvant endocrine therapy. As a minimum, patients had to have receptor-positive tumors, which were defined either as estrogen receptor (ER) and/or progesterone receptor (PgR) ≥ 10 fmol/mg cytosol protein; or ≥ 10% of the tumor cells positive by immunocytochemical evaluation. * Adequate bone marrow function (white blood cell count \[WBC\] \> 3.0 x 109 /L, platelets ≥ 100.0 x 109 /L, and hemoglobin \> 10 g/dL). * Documented evidence of adequate renal function (creatinine \< 180 µmol/L) and hepatic function (bilirubin \< 30 µmol/L, alanine aminotransferase (ALT) \< 1.5 x upper normal limit of the laboratory). * Life expectancy of at least 24 months at the time of enrollment. * Written voluntary informed consent prior to initiation of any study procedure. * Willingness to undergo all scheduled tests and examinations for evaluation of bone density and bone metabolism, and lipid profiles in addition to the standard assessments for monitoring their breast cancer status.

Exclusion criteria

* Patients with distant metastases as defined by the criteria of the Danish Breast Cancer Co-operative Group (DBCCOG). * Pre-existing bone disease (e.g. osteomalacia, osteogenesis imperfecta, Paget's disease). * Patients receiving bisphosphonates for more than 3 months before randomization. * Chronic treatment with drugs known to interfere with bone metabolism, e.g. * Anti-convulsants within the past year. * Corticosteroids at doses greater than the equivalent of 5 mg/day prednisone for more than two weeks in the past 6 months (prior to randomization). * Any previous treatment with sodium fluoride at daily doses ≥ 5 mg/day for a period exceeding 1 month. * Anabolic steroids in the past 12 months. * Long term use of coumarin derivatives and heparin at the time of randomization. * Metabolic diseases known to interfere with bone metabolism (e.g., Hyperparathyroidism, hypoparathyroidism, uncontrolled thyroid disease, Cushing's disease, vitamin D deficiency, malabsorption syndrome, etc.). * Treatment with lipid-lowering agents within the 3 months prior to randomization (this exclusion criterion did not apply to patients randomized in the United Kingdom). * Patients receiving other anti-cancer treatment. * Previous neoadjuvant / adjuvant chemotherapy and /or previous adjuvant endocrine therapy (e.g., anti-estrogens, AIs). * History of previous or concomitant malignancy within the past 5 years other than adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who had a previous other malignancy must have been disease free for five years. Patients with endometrial cancer and/or invasive breast cancer at any time in their medical history were excluded. Patients with invasive bilateral breast cancer were excluded. Patients with vaginal discharge/ vaginal bleeding with evidence of malignancy were excluded. * Any other non-malignant systemic diseases (cardiovascular, renal, hepatic, lung embolism, etc.) which would prevent prolonged follow-up.

Design outcomes

Primary

Measure	Time frame	Description
Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4)	Baseline, 24 months	Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. All DXA scans were evaluated by a central reader.

Secondary

Measure	Time frame	Description
Percent Change From Baseline of Bone Mineral Density (BMD) of Total Hip	Baseline, 60 months	Total hip BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. All DXA scans were evaluated by a central reader.
Median Percent Change From Baseline of Serum Markers of Bone Turnover	Baseline, 60 months	Bone turnover markers (fasting serum procollagen-I extension peptide \[P1NP\], C-telopeptide \[CTX\], skeletal bone-specific alkaline phosphatase \[BSAP, N-telopeptide \[NTX\]) were measured at baseline/screening and at each visit thereafter. A central laboratory was used to analyze the samples. The analysis of bone markers was based on analysis of variance of the regression slopes calculated for each individual patient and each bone marker over time. In the following summary, only the median treatment group percent change from baseline (and range) at 5 years is presented for each bone marker.
Percentage Change From Baseline in Serum Lipids at 5 Years	Baseline, 60 months	Serum lipid profile (fasting serum cholesterol \[total, HDL and calculated LDL\], triglycerides, and lipoprotein \[a\]) were measured at baseline/screening and at each visit thereafter. A central laboratory was used to analyze the samples. The analysis of serum lipids was on the treatment group median percent change from baseline (and range) at 5 years.
Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine	Baseline, 60 months	Lumbar spine (L2-L4)BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. All DXA scans were evaluated by a central reader.
Time to Disease Recurrence or Death	60 months	Disease-free survival was defined as the interval between randomization and earliest confirmed event of loco-regional recurrence, distant metastases, invasive contralateral breast cancer, or death from any cause.
Time to Overall Survival Events	60 Months	Overall survival was measured from date of randomization to date of death.
Number of Participants With Clinically Relevant Changes From Baseline in Cholesterol	Baseline, 60 months	Serum lipid profile (fasting serum cholesterol \[total, HDL and calculated LDL\], triglycerides, and lipoprotein \[a\]) were measured at baseline/screening and at each visit thereafter. A central laboratory was used to analyze the samples. Numbers are not additive, as patients could be included in multiple rows.

Countries

Denmark, United Kingdom

Participant flow

Participants by arm

Arm	Count
Letrozole 2.5 mg once daily (q.d.)orally for 5 years	133
Tam-Let Tamoxifen 20 mg once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.	130
Total	263

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Administrative Problems	2	1
Overall Study	Adverse Event	24	33
Overall Study	Death	2	2
Overall Study	Disease Progression	14	9
Overall Study	New therapy for 2nd non-breast prim canc	1	0
Overall Study	Protocol Violation	0	1
Overall Study	Withdrawal by Subject	1	3

Baseline characteristics

Characteristic	Letrozole	Tam-Let	Total
Age, Continuous	61.4 years STANDARD_DEVIATION 6.1	61.8 years STANDARD_DEVIATION 6.2	61.6 years STANDARD_DEVIATION 6.2
Sex: Female, Male Female	133 Participants	130 Participants	263 Participants
Sex: Female, Male Male	0 Participants	0 Participants	0 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	— / —	— / —
other Total, other adverse events	113 / 133	110 / 130
serious Total, serious adverse events	50 / 133	41 / 130

Outcome results

Primary

Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4)

Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. All DXA scans were evaluated by a central reader.

Time frame: Baseline, 24 months

Population: The safety population consisted of only patients who took randomized therapy for at least one day. The number of patients in each treatment arm who had completed 2 years of the study and had centrally assessed measurements of lumbar spine or total hip BMD.

Arm	Measure	Value (MEDIAN)
Letrozole	Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4)	-4.63 Percent Change
Tam-Let	Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4)	0.37 Percent Change

Secondary

Median Percent Change From Baseline of Serum Markers of Bone Turnover

Bone turnover markers (fasting serum procollagen-I extension peptide \[P1NP\], C-telopeptide \[CTX\], skeletal bone-specific alkaline phosphatase \[BSAP, N-telopeptide \[NTX\]) were measured at baseline/screening and at each visit thereafter. A central laboratory was used to analyze the samples. The analysis of bone markers was based on analysis of variance of the regression slopes calculated for each individual patient and each bone marker over time. In the following summary, only the median treatment group percent change from baseline (and range) at 5 years is presented for each bone marker.